NDUFB8 antibody targets the NDUFB8 protein, a crucial subunit of mitochondrial Complex I (NADH:ubiquinone oxidoreductase) in the electron transport chain. Complex I, the largest respiratory complex, facilitates NADH oxidation and proton translocation, essential for ATP synthesis. NDUFB8. encoded by the nuclear *NDUFB8* gene, is one of 45 subunits composing Complex I, playing a structural and functional role in its assembly and catalytic activity. Antibodies against NDUFB8 are widely used to study Complex I expression, stability, and mitochondrial dysfunction.
NDUFB8 antibodies are critical tools in research on mitochondrial disorders (e.g., Leigh syndrome), neurodegenerative diseases (e.g., Parkinson’s), and cancer, where Complex I deficiencies or mutations are implicated. They enable detection of NDUFB8 via Western blotting, immunofluorescence, or immunohistochemistry, helping assess protein levels in tissues, cell lines, or animal models. Specificity is validated using knockdown/knockout controls, confirming the absence of cross-reactivity with other subunits.
Commercial NDUFB8 antibodies are typically raised in rabbits or mice using synthetic peptides or recombinant proteins. Researchers prioritize antibodies validated for multiple applications and species reactivity (human, mouse, rat). Proper validation ensures accurate interpretation of mitochondrial health and disease mechanisms. As mitochondrial research expands, NDUFB8 antibodies remain indispensable for elucidating metabolic reprogramming, oxidative stress responses, and therapeutic interventions targeting cellular energy pathways.